Patterns of cannabis use and prospective associations with health issues among young males.

BACKGROUND AND AIMS: To test prospective associations between cannabis disorder symptoms/frequency of cannabis use and health issues and to investigate stability versus transience in cannabis use trajectories. DESIGN: Two waves of data collection from the longitudinal Cohort Study on Substance Use Risk Factors (C-SURF). SETTING: A representative sample of young Swiss men in their early 20s from the general population. PARTICIPANTS: A total of 5084 young men (mean age 19.98 ± 1.19 years at time 1). MEASUREMENTS: Cannabis use (life-time use, frequency of use, cannabis disorder symptoms) and self-reported measures of health issues (depression, mental/physical health, health consequences) were assessed. Significant changes in cannabis use were tested using t-test/Wilcoxon's rank test for paired data. Cross-lagged panel models provided evidence regarding longitudinal associations between cannabis use and health issues. FINDINGS: Most of the participants (84.5%) remained in the same use category and cannabis use kept to similar levels at times 1 and 2 (P = 0.114 and P = 0.755; average of 15 ± 2.8 months between times 1 and 2). Cross-lagged panel models showed that cannabis disorder symptoms predicted later health issues (e.g. depression, β = 0.087, P < 0.001; health consequences, β = 0.045, P < 0.05). The reverse paths from health issues to cannabis disorder symptoms and the cross-lagged panel model between frequency of cannabis use and health issues were non-significant. CONCLUSIONS: Patterns of cannabis use showed substantial continuity among young Swiss men in their early 20s. The number of symptoms of cannabis use disorder, rather than the frequency of cannabis use, is a clinically important measure of cannabis use among young Swiss men.

Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.

Cilengitide, a cyclicized arginine-glycine-aspartic acid-containing pentapeptide, potently blocks ανβ3 and ανβ5 integrin activation. Integrins are upregulated in many malignancies and mediate a wide variety of tumor-stroma interactions. Cilengitide and other integrin-targeting therapeutics have preclinical activity against many cancer subtypes including glioblastoma (GBM), the most common and deadliest CNS tumor. Cilengitide is active against orthotopic GBM xenografts and can augment radiotherapy and chemotherapy in these models. In Phase I and II GBM trials, cilengitide and the combination of cilengitide with standard temozolomide and radiation demonstrate consistent antitumor activity and a favorable safety profile. Cilengitide is currently under evaluation in a pivotal, randomized Phase III study (Cilengitide in Combination With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Phase III Randomized Clinical Trial [CENTRIC]) for newly diagnosed GBM. In addition, randomized controlled Phase II studies with cilengitide are ongoing for non-small-cell lung cancer and squamous cell carcinoma of the head and neck. Cilengitide is the first integrin inhibitor in clinical Phase III development for oncology.

Neutral atoms in ionic lattices: Excited states of KCl:Ag(0)

The optical-absorption spectrum of a cationic Ag0 atom in a KCl crystal has been studied theoretically by means of a series of cluster models of increasing size. Excitation energies have been determined by means of a multiconfigurational self-consistent field procedure followed by a second-order perturbation correlation treatment. Moreover results obtained within the density-functional framework are also reported. The calculations confirm the assignment of bands I and IV to transitions of the Ag-5s electron into delocalized states with mainly K-4s,4p character. Bands II and III have been assigned to internal transitions on the Ag atom, which correspond to the atomic Ag-4d to Ag-5s transition. We also determine the lowest charge transfer (CT) excitation energy and confirm the assignment of band VI to such a transition. The study of the variation of the CT excitation energy with the Ag-Cl distance R gives additional support to a large displacement of the Cl ions due to the presence of the Ag0 impurity. Moreover, from the present results, it is predicted that on passing to NaCl:Ag0 the CT onset would be out of the optical range while the 5s-5p transition would undergo a redshift of 0.3 eV. These conclusions, which underline the different character of involved orbitals, are consistent with experimental findings. The existence of a CT transition in the optical range for an atom inside an ionic host is explained by a simple model, which also accounts for the differences with the more common 3d systems. The present study sheds also some light on the R dependence of the s2-sp transitions due to s2 ions like Tl+.

Actualizaciones en psicopatología infantil (0-5 años)

Aquest manual pretèn ser una obra introductòria a la psicopatologia infantil, disciplina força recent però d'evolució molt ràpida. L'objectiu és delimitar les etapes d'estudi en aquesta disciplina i fer una aportació introductòria a la temàtica. És per tant una obra que se sap parcial i lacunar.

[Voyage en Italie : 1824-1830]. , Chapelle de Pazzi dans le cloître du couvent de Ste Croix à Florence, sur une échelle de 0,0015 PM : [élévation principale et quatre profils] : [dessin] / h. L. [Henri Labrouste]

Référence bibliographique : Weigert, 139

[Voyage en Italie : 1824-1830]. , S. Spirito, Sur une Echelle de 0,002 1/2 P.M. : [plan d'ensemble] : [dessin] / h. L. [Henri Labrouste]

Référence bibliographique : Weigert, 133

[Voyage en Italie : 1824-1830]. , S. Miniato, sur une Echelle de 0,005 p.m : [plan] : [dessin] / h. L. [Henri Labrouste]

Référence bibliographique : Weigert, 129

[Voyage en Italie : 1824-1830]. , S. Miniato. Chapelle souterraine, sur une Echelle de 0,005 p.m. : [plan] : [dessin] / h. L. [Henri Labrouste]

Référence bibliographique : Weigert, 130

[Voyage en Italie : 1824-1830]. , S. Miniato, sur une Echelle de 0,005 p.m. : [coupe longitudinale] : [dessin] / h. L. [Henri Labrouste]

Référence bibliographique : Weigert, 132

[Voyage en Italie : 1824-1830]. , Monument connu sous le nom de chapelle de Phalaris, sur une Echelle de 0,010 P.M. : [élévation principale, élévation latérale, plan d'ensemble et détail de l'ante, profils de l'ante et du soubassement] : [dessin] / h. L. [Henri Labrouste]

Référence bibliographique : Weigert, 179

[Voyage en Italie : 1824-1830]. , Porte de la chapelle de Phalaris à Agrigente, sur une Echelle de 0,40 P.M. : [profil de la corniche surmontant le linteau, élévation de la porte] : [dessin] / h. L. [Henri Labrouste]

Référence bibliographique : Weigert, 181

[Voyage en Italie : 1824-1830]. , Temple de la Concorde à Agrigente, sur une Echelle de 0,005 P.M. : [plan] : [dessin] / h. L. [Henri Labrouste]

Référence bibliographique : Weigert, 183

[Voyage en Italie : 1824-1830]. , Temple d'Esculape, sur une Echelle de 0,005 P.M. : [élévation principale, plan d'ensemble, coupe longitidinale et deux profils de détails] : [dessin] / h. L. [Henri Labrouste]

Référence bibliographique : Weigert, 185

[Voyage en Italie : 1824-1830]. , Temple de Junon Lucine à Agrigente, sur une Echelle de 0,005 P.M. : [plan d'ensemble, coupe longitudinale, détail d'un claveau de l'entablement] : [dessin] / h. L. [Henri Labrouste]

Référence bibliographique : Weigert, 190